LORAZEPAM injection

Երկիր: Ամերիկայի Միացյալ Նահանգներ

Լեզու: անգլերեն

Աղբյուրը: NLM (National Library of Medicine)

Ակտիվ բաղադրիչ:

LORAZEPAM (UNII: O26FZP769L) (LORAZEPAM - UNII:O26FZP769L)

Հասանելի է:

Civica, Inc.

Կառավարման երթուղին:

INTRAMUSCULAR

Ռեկվիզորի տեսակը:

PRESCRIPTION DRUG

Թերապեւտիկ ցուցումներ:

Lorazepam Injection is indicated for the treatment of status epilepticus. Lorazepam Injection is indicated in adult patients for preanesthetic medication, producing sedation (sleepiness or drowsiness), relief of anxiety, and a decreased ability to recall events related to the day of surgery. It is most useful in those patients who are anxious about their surgical procedure and who would prefer to have diminished recall of the events of the day of surgery (see PRECAUTIONS, Information for Patients ). Lorazepam Injection is contraindicated in patients with a known sensitivity to benzodiazepines or its vehicle (polyethylene glycol, propylene glycol, and benzyl alcohol), in patients with acute narrow-angle glaucoma, or in patients with sleep apnea syndrome. It is also contraindicated in patients with severe respiratory insufficiency, except in those patients requiring relief of anxiety and/or diminished recall of events while being mechanically ventilated. The use of Lorazepam Injection intra-arterially is contra

Ապրանքի ամփոփագիր:

Lorazepam Injection, USP is available in the following dosage strength as a single-dose vial:   2 mg per mL, NDC 72572-380-25, 25 x 1 mL vial For IM or IV injection. Store in a refrigerator. PROTECT FROM LIGHT. Use carton to protect contents from light.

Լիազորման կարգավիճակը:

New Drug Application

Ապրանքի հատկությունները

LORAZEPAM- LORAZEPAM INJECTION
CIVICA, INC.
----------
LORAZEPAM INJECTION, USP
CIV
FOR INTRAVENOUS AND INTRAMUSCULAR USE
NOT FOR USE IN NEONATES
CONTAINS BENZYL ALCOHOL
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE,
MISUSE, AND ADDICTION; AND DEPENDENCE AND WITHDRAWAL
REACTIONS
CONCOMITANT USE OF BENZODIAZEPINES AND OPIOIDS MAY RESULT IN
PROFOUND SEDATION, RESPIRATORY DEPRESSION, COMA, AND DEATH. RESERVE
CONCOMITANT PRESCRIBING OF THESE DRUGS IN PATIENTS FOR WHOM
ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE. LIMIT DOSAGES AND
DURATIONS TO THE MINIMUM REQUIRED. FOLLOW PATIENTS FOR SIGNS AND
SYMPTOMS OF RESPIRATORY DEPRESSION AND SEDATION (SEE
WARNINGS AND PRECAUTIONS).
THE USE OF BENZODIAZEPINES, INCLUDING LORAZEPAM INJECTION, EXPOSES
USERS TO RISKS OF ABUSE, MISUSE, AND ADDICTION, WHICH CAN LEAD TO
OVERDOSE OR DEATH. ABUSE AND MISUSE OF BENZODIAZEPINES COMMONLY
INVOLVE CONCOMITANT USE OF OTHER MEDICATIONS, ALCOHOL, AND/OR ILLICIT
SUBSTANCES, WHICH IS ASSOCIATED WITH AN INCREASED FREQUENCY OF
SERIOUS ADVERSE OUTCOMES. BEFORE PRESCRIBING LORAZEPAM INJECTION
AND THROUGHOUT TREATMENT, ASSESS EACH PATIENT’S RISK FOR ABUSE,
MISUSE, AND ADDICTION (SEE WARNINGS).
THE CONTINUED USE OF BENZODIAZEPINES FOR SEVERAL DAYS TO WEEKS MAY
LEAD TO CLINICALLY SIGNIFICANT PHYSICAL DEPENDENCE. THE RISKS OF
DEPENDENCE AND WITHDRAWAL INCREASE WITH LONGER TREATMENT DURATION
AND HIGHER DAILY DOSE. ALTHOUGH LORAZEPAM INJECTION IS INDICATED ONLY
FOR INTERMITTENT USE (SEE INDICATIONS AND USAGE AND DOSAGE AND
ADMINISTRATION), IF USED MORE FREQUENTLY THAN RECOMMENDED,
ABRUPT DISCONTINUATION OR RAPID DOSAGE REDUCTION OF LORAZEPAM
INJECTION MAY PRECIPITATE ACUTE WITHDRAWAL REACTIONS, WHICH CAN BE
LIFE-THREATENING. FOR PATIENTS USING LORAZEPAM INJECTION MORE
FREQUENTLY THAN RECOMMENDED, TO REDUCE THE RISK OF WITHDRAWAL
REACTIONS, USE A GRADUAL TAPER TO DISCONTINUE LORAZEPAM INJECTION
(SEE WARNINGS).
DESCRIPTION
Lorazepam, a benzodiazepine with antianxiety, sedative, and
anticonvulsant effects, is
intended for the intramuscular or int